/BCEL

BCEL Stock - Atreca, Inc.

Q: What is the analyst price target for BCEL?

Analyst price target information is not currently available for BCEL.

Q: What is BCEL's market cap?

Market capitalization information is not currently available for BCEL.

Healthcare|Biotechnology|NASDAQ

$0.09-1.32%

$0.00 (-1.32%) • Jun 14

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+4344.4%upside

Target: $4.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BCEL

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.03

52W High$1.20

52W Low$0.05

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	$770,000	$851,000	$1.35M	$2.13M	$961,000
Gross Profit	$-6,311,000	$-3,699,000	N/A	N/A	N/A
Gross Margin	-819.6%	-434.7%	0.0%	0.0%	0.0%
Operating Income	$-97,525,000	$-109,452,000	$-87,526,000	$-70,437,000	$-38,612,000
Net Income	$-97,157,000	$-109,326,000	$-86,335,000	$-67,484,000	$-37,940,000
Net Margin	-12617.8%	-12846.8%	-6381.0%	-3162.3%	-3948.0%
EPS	$-2.35	$-2.95	$-2.70	$-4.26	$-11.75

Company Overview

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.

Visit Website

Earnings History & Surprises

BCEL

Beat Rate

50%

Last 16 quarters

Avg Surprise

+1.6%

EPS vs Estimate

Beats / Misses

8/7

1 met exactly

Latest EPS

$-0.39

Q4 2023

EPS Surprise History

Q1 22

-5.3%

$-0.79vs$-0.75

Q2 22

+16.7%

$-0.65vs$-0.78

Q3 22

-2.9%

$-0.72vs$-0.70

Q4 22

+17.8%

$-0.60vs$-0.73

Q1 23

-1.9%

$-0.55vs$-0.54

Q2 23

+3.6%

$-0.54vs$-0.56

Q3 23

+12.5%

$-0.49vs$-0.56

Q4 23

-8.3%

$-0.39vs$-0.36

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2024	Nov 12, 2024	—	—	—	—
Q3 2024	Aug 8, 2024	$-0.35	—	—	—
Q2 2024	Jun 19, 2024	$-0.35	—	—	—
Q1 2024	Mar 27, 2024	$-0.35	—	—	—
Q4 2023	Nov 14, 2023	$-0.36	$-0.39	-8.3%	✗ MISS
Q3 2023	Aug 10, 2023	$-0.56	$-0.49	+12.5%	✓ BEAT
Q2 2023	May 10, 2023	$-0.56	$-0.54	+3.6%	✓ BEAT
Q1 2023	Mar 29, 2023	$-0.54	$-0.55	-1.9%	✗ MISS
Q4 2022	Nov 10, 2022	$-0.73	$-0.60	+17.8%	✓ BEAT
Q3 2022	Aug 8, 2022	$-0.70	$-0.72	-2.9%	✗ MISS
Q2 2022	May 11, 2022	$-0.78	$-0.65	+16.7%	✓ BEAT
Q1 2022	Mar 3, 2022	$-0.75	$-0.79	-5.3%	✗ MISS
Q4 2021	Nov 2, 2021	$-0.75	$-0.74	+1.3%	✓ BEAT
Q3 2021	Aug 11, 2021	$-0.71	$-0.72	-1.4%	✗ MISS
Q2 2021	May 13, 2021	$-0.65	$-0.70	-7.7%	✗ MISS
Q1 2021	Feb 25, 2021	$-0.63	$-0.63	0.0%	= MET
Q4 2020	Nov 12, 2020	$-0.60	$-0.66	-10.0%	✗ MISS
Q3 2020	Aug 12, 2020	$-0.77	$-0.71	+7.8%	✓ BEAT
Q2 2020	May 14, 2020	$-0.74	$-0.73	+1.4%	✓ BEAT
Q1 2020	Mar 11, 2020	$-0.66	$-0.65	+1.5%	✓ BEAT